Cargando…

Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals

Ceftazidime-avibactam (CZA) is the combination of a third-generation cephalosporin and a new non-β-lactam β-lactamase inhibitor capable of inactivating class A, C, and some D β-lactamases. From a collection of 2,727 clinical isolates of Enterobacterales (n = 2,235) and P. aeruginosa (n = 492) that w...

Descripción completa

Detalles Bibliográficos
Autores principales: Mojica, María Fernanda, De La Cadena, Elsa, García-Betancur, Juan Carlos, Porras, Jessica, Novoa-Caicedo, Isabella, Páez-Zamora, Laura, Pallares, Christian, Appel, Tobias Manuel, Radice, Marcela A., Castañeda-Méndez, Paulo, Gales, Ana C., Munita, José M., Villegas, María Virginia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117078/
https://www.ncbi.nlm.nih.gov/pubmed/36877058
http://dx.doi.org/10.1128/msphere.00651-22
_version_ 1785028554116825088
author Mojica, María Fernanda
De La Cadena, Elsa
García-Betancur, Juan Carlos
Porras, Jessica
Novoa-Caicedo, Isabella
Páez-Zamora, Laura
Pallares, Christian
Appel, Tobias Manuel
Radice, Marcela A.
Castañeda-Méndez, Paulo
Gales, Ana C.
Munita, José M.
Villegas, María Virginia
author_facet Mojica, María Fernanda
De La Cadena, Elsa
García-Betancur, Juan Carlos
Porras, Jessica
Novoa-Caicedo, Isabella
Páez-Zamora, Laura
Pallares, Christian
Appel, Tobias Manuel
Radice, Marcela A.
Castañeda-Méndez, Paulo
Gales, Ana C.
Munita, José M.
Villegas, María Virginia
author_sort Mojica, María Fernanda
collection PubMed
description Ceftazidime-avibactam (CZA) is the combination of a third-generation cephalosporin and a new non-β-lactam β-lactamase inhibitor capable of inactivating class A, C, and some D β-lactamases. From a collection of 2,727 clinical isolates of Enterobacterales (n = 2,235) and P. aeruginosa (n = 492) that were collected between 2016 and 2017 from five Latin American countries, we investigated the molecular resistance mechanisms to CZA of 127 (18/2,235 [0.8%] Enterobacterales and 109/492 [22.1%] P. aeruginosa). First, by qPCR for the presence of genes encoding KPC, NDM, VIM, IMP, OXA-48-like, and SPM-1 carbapenemases, and second, by whole-genome sequencing (WGS). From the CZA-resistant isolates, MBL-encoding genes were detected in all 18 Enterobacterales and 42/109 P. aeruginosa isolates, explaining their resistant phenotype. Resistant isolates that yielded a negative qPCR result for any of the MBL encoding genes were subjected to WGS. The WGS analysis of the 67 remaining P. aeruginosa isolates showed mutations in genes previously associated with reduced susceptibility to CZA, such as those involved in the MexAB-OprM efflux pump and AmpC (PDC) hyperproduction, PoxB (bla(OXA-50-like)), FtsI (PBP3), DacB (PBP4), and OprD. The results presented here offer a snapshot of the molecular epidemiological landscape for CZA resistance before the introduction of this antibiotic into the Latin American market. Therefore, these results serve as a valuable comparison tool to trace the evolution of the resistance to CZA in this carbapenemase-endemic geographical region. IMPORTANCE In this manuscript, we determine the molecular mechanisms of ceftazidime-avibactam resistance in Enterobacterales and P. aeruginosa isolates from five Latin American countries. Our results reveal a low rate of resistance to ceftazidime-avibactam among Enterobacterales; in contrast, resistance in P. aeruginosa has proven to be more complex, as it might involve multiple known and possibly unknown resistance mechanisms.
format Online
Article
Text
id pubmed-10117078
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-101170782023-04-21 Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals Mojica, María Fernanda De La Cadena, Elsa García-Betancur, Juan Carlos Porras, Jessica Novoa-Caicedo, Isabella Páez-Zamora, Laura Pallares, Christian Appel, Tobias Manuel Radice, Marcela A. Castañeda-Méndez, Paulo Gales, Ana C. Munita, José M. Villegas, María Virginia mSphere Research Article Ceftazidime-avibactam (CZA) is the combination of a third-generation cephalosporin and a new non-β-lactam β-lactamase inhibitor capable of inactivating class A, C, and some D β-lactamases. From a collection of 2,727 clinical isolates of Enterobacterales (n = 2,235) and P. aeruginosa (n = 492) that were collected between 2016 and 2017 from five Latin American countries, we investigated the molecular resistance mechanisms to CZA of 127 (18/2,235 [0.8%] Enterobacterales and 109/492 [22.1%] P. aeruginosa). First, by qPCR for the presence of genes encoding KPC, NDM, VIM, IMP, OXA-48-like, and SPM-1 carbapenemases, and second, by whole-genome sequencing (WGS). From the CZA-resistant isolates, MBL-encoding genes were detected in all 18 Enterobacterales and 42/109 P. aeruginosa isolates, explaining their resistant phenotype. Resistant isolates that yielded a negative qPCR result for any of the MBL encoding genes were subjected to WGS. The WGS analysis of the 67 remaining P. aeruginosa isolates showed mutations in genes previously associated with reduced susceptibility to CZA, such as those involved in the MexAB-OprM efflux pump and AmpC (PDC) hyperproduction, PoxB (bla(OXA-50-like)), FtsI (PBP3), DacB (PBP4), and OprD. The results presented here offer a snapshot of the molecular epidemiological landscape for CZA resistance before the introduction of this antibiotic into the Latin American market. Therefore, these results serve as a valuable comparison tool to trace the evolution of the resistance to CZA in this carbapenemase-endemic geographical region. IMPORTANCE In this manuscript, we determine the molecular mechanisms of ceftazidime-avibactam resistance in Enterobacterales and P. aeruginosa isolates from five Latin American countries. Our results reveal a low rate of resistance to ceftazidime-avibactam among Enterobacterales; in contrast, resistance in P. aeruginosa has proven to be more complex, as it might involve multiple known and possibly unknown resistance mechanisms. American Society for Microbiology 2023-03-06 /pmc/articles/PMC10117078/ /pubmed/36877058 http://dx.doi.org/10.1128/msphere.00651-22 Text en Copyright © 2023 Mojica et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Mojica, María Fernanda
De La Cadena, Elsa
García-Betancur, Juan Carlos
Porras, Jessica
Novoa-Caicedo, Isabella
Páez-Zamora, Laura
Pallares, Christian
Appel, Tobias Manuel
Radice, Marcela A.
Castañeda-Méndez, Paulo
Gales, Ana C.
Munita, José M.
Villegas, María Virginia
Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals
title Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals
title_full Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals
title_fullStr Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals
title_full_unstemmed Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals
title_short Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals
title_sort molecular mechanisms of resistance to ceftazidime/avibactam in clinical isolates of enterobacterales and pseudomonas aeruginosa in latin american hospitals
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117078/
https://www.ncbi.nlm.nih.gov/pubmed/36877058
http://dx.doi.org/10.1128/msphere.00651-22
work_keys_str_mv AT mojicamariafernanda molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals
AT delacadenaelsa molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals
AT garciabetancurjuancarlos molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals
AT porrasjessica molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals
AT novoacaicedoisabella molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals
AT paezzamoralaura molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals
AT pallareschristian molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals
AT appeltobiasmanuel molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals
AT radicemarcelaa molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals
AT castanedamendezpaulo molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals
AT galesanac molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals
AT munitajosem molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals
AT villegasmariavirginia molecularmechanismsofresistancetoceftazidimeavibactaminclinicalisolatesofenterobacteralesandpseudomonasaeruginosainlatinamericanhospitals